Track topics on Twitter Track topics that are important to you
Empagliflozin tablets reduced the risk of cardiovascular death by 38 percent in people with type 2 diabetes and established cardiovascular disease (CVD), according to a randomized, placebo-controlled trial of more than 7,000 patients. And new analyses demonstrate a similar benefit was seen in all patients, regardless of blood sugar levels at baseline or after the introduction of background treatment.
Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...